The Life Sciences team advised Korro Bio on a collaboration with Novo Nordisk to advance the discovery and development of new genetic medicines, with the initial target of treating cardiometabolic diseases. The collaboration brings Novo Nordisk’s deep cardiometabolic disease understanding and drug development experience together with Korro’s proprietary platform to develop RNA editing product candidates for two undisclosed targets. Korro will advance up to two programs through preclinical development after which point Novo Nordisk could further advance the programs through clinical studies.
Korro Bio is a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to affect a precise yet transient single base edit.
The Goodwin team consisted of Chris Denn and Xiaowei Wu with support from Kingsley Taft, Marianne Sarrazin, Will Wang and Eunice Chang.
For more information on the collaboration, please read the press release.